Cardinal Health reported fiscal year-end results on August 11, and the Street's response has been immediate and nearly unanimous — six firms lifted price targets on the same day, the clearest post-earnings signal of the week in healthcare distribution.
The analyst move is the standout story. Evercore ISI, Morgan Stanley, Mizuho, UBS, Wells Fargo, and Baird all raised targets this morning, none cut their rating, and the direction has been uniformly higher. Morgan Stanley moved to $265 from $255 while maintaining Overweight. Wells Fargo made the boldest revision, lifting to $277 from $245. UBS pushed its target to $280 — now the highest on the Street — from $274. The consensus mean reached $263.60, roughly 10% above the current price of $240.26. That gap has widened since the pre-earnings preview flagged around 9% upside, meaning the Street accelerated its conviction on the back of the print rather than dialling it back. EPS momentum confirms the enthusiasm: Cardinal ranks in the 92nd percentile on 30-day EPS momentum and the 98th percentile on forward EPS year-on-year growth — the two strongest factor readings in the snapshot.
The bull and bear debate has sharpened but not changed shape. Bulls point to the radiopharmaceuticals expansion, specialty distribution scale, and free cash flow durability — the same themes flagged pre-earnings, now with a result behind them. The EV/EBITDA multiple has drifted slightly lower over 30 days to 12.9x, while the trailing PE sits at 18x, suggesting the stock has not yet been re-rated aggressively despite the target-price push. Bears retain their structural concerns: generic-dependent revenue as the patent cliff eases, international exposure through the GMPD segment to geopolitical disruption, and the competitive intensity of US pharmaceutical wholesale. The dividend score ranks in the 90th percentile, which provides some cushion for income-oriented holders, but the dividend data in the snapshot is dated to 2022 and should not be relied upon for current yield calculations.
Positioning offers little drama, which is itself notable. Short interest has fallen 26% over the past month to 2.7% of free float — a level low enough that bears have largely stepped aside. Borrow availability is essentially unlimited, with more than 220 million shares available to lend against roughly 6.5 million short. Cost to borrow has dropped 22% over the week to just 0.29%, confirming there is no squeeze pressure and no particular urgency from the short side. Options positioning is similarly relaxed — the put/call ratio of 0.73 sits marginally below its 20-day average of 0.74, with a z-score of -0.45, meaning there is no elevated demand for downside protection despite an earnings event. Peers MCK and COR both gained more than 8-9% on the week, suggesting the earnings-driven lift has pulled the whole drug distribution cohort higher rather than leaving Cardinal Health exposed as an outlier.
The week's setup is therefore cleaner than most post-earnings prints: targets moved up, shorts moved out, and the borrow market is indifferent. What to watch now is whether the stock closes the gap toward the $263-$280 analyst target range — and whether any holdouts, notably JP Morgan's dated Neutral at $215 (flagged in prior articles as increasingly disconnected from consensus), update their view in the days ahead.
See the live data behind this article on ORTEX.
Open CAH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
